knowledge -WSS

knowledge

author：explore 2025-10-01 04:11:23 - browse：93395

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Biotech venture capitalists face new demands from investors

leisure time

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Humana cuts profit projections as Medicare Advantage costs soar

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Copay coupons to count toward deductibles, after Biden court move

New brain studies show LSD's effects on the brain in full color

Option Care buys Amedisys in $3.6 billion home care deal

hotspot

knowledge

focus

The cancer drug shortage isn’t new — and neither are the solutions

7 people shot in DC, police say

Psychedelics group wrestles with new pharma identity

How digital therapeutics firms are pivoting after Pear's bankruptcy

Supreme Court strikes down use of affirmative action

Did the public have the right to know Arthur Ashe had AIDS?

Heart attack and stroke risk calculators need revising

The tragedy of Johnson & Johnson’s Covid vaccine

23andMe had bad news about my health. I wish a person had delivered it

Biotech venture capitalists face new demands from investors

leisure time

Did the public have the right to know Arthur Ashe had AIDS?

Did the public have the right to know Arthur Ashe had AIDS?

Community addresses injustice for Long Island mothers

Humana cuts profit projections as Medicare Advantage costs soar

Pfizer's Covid pill remains 89% effective in final analysis, company says

Did the public have the right to know Arthur Ashe had AIDS?

knowledge

focus

leisure time

Wikipedia